alexa Diabetes Insipidus | Canada| PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Relevant Topics

Diabetes Insipidus

  • Diabetes Insipidus

    Diabetes insipidus is an uncommon disorder characterized by intense thirst, despite the drinking of fluids (polydipsia), and the excretion of large amounts of urine (polyuria).Diabetes insipidus is caused by abnormality in the functioning or levels of antidiuretic hormone (ADH), also known of as vasopressin.It is manufactured in the hypothalamus and stored in the pituitary gland, ADH helps to regulate the amount of fluid in the body. ADH is released from the pituitary gland which prevents the excretion of fluids from the body in the form of urine. There are four types of diabetes insipidus Central diabetis insipidus or Cranial Diabetis insipidus and Nephrogenic diabetes insipidus.

  • Diabetes Insipidus

    Treatment mainly aim to reduce to reduce the amount of urine your body produces. Mild cranial diabetes insipidus may not require any medical treatment, the only think to do is to increase the amount of water consumption. Central diabetes insipidus may be controlled with desmopressin,it is a synthetic analogue of antidiuretic hormone (ADH). Desmopressin is available either an injection, a nasal spray, or tablets Generally, it can be administered 2-3 times per day. Patients may require hospitalization to establish fluid needs. Frequent electrolyte monitoring is recommended during the initial phase of treatment. Nephrogenic DI is treated with anti-inflammatory medicines and diuretics.

  • Diabetes Insipidus

    The extrapolated incidence in Canada is 4,876. The population estimated used is 32,507,874.

  • Diabetes Insipidus

    1)The McGill Geriatric Lithium-Induced Diabetes Insipidus Clinical Study (McGLIDICS. 2) GSK3beta mediates renal response to vasopressin by modulating adenylate cyclase activity. 3) Characterization of D150E and G196D aquaporin-2 mutations responsible for nephrogenic diabetes insipidus: importance of a mild phenotype.

Expert PPTs
Speaker PPTs

High Impact List of Articles

Conference Proceedings